Significance of Inflammatory Pseudotumors in Patients with a History of Bladder Cancer - 09/08/11
, Dov Pode a, Amos Shapiro a, Kevin C. Zorn c, Galina Pizov b
Reprint requests: Ofer N. Gofrit, M.D., Section of Urology, Department of Surgery, The University of Chicago Hospitals, 5841 S. Maryland Avenue, MC 6038, Chicago, IL 60637.Resumen |
Objective |
To study the significance of inflammatory pseudotumor (IPT) in patients with a history of bladder cancer.
Methods |
We surveyed our hospital database for patients who developed IPT during follow-up of bladder cancer. The original histologic blocks were reviewed and immunostained for vimentin, anaplastic large cell lymphoma (ALK), and pancytokeratin.
Results |
Between the years 1988 and 2005, a total of 809 patients were registered in the database, and 16 patients (2%) developed IPT during follow-up. All patients had initial high-grade tumor. Immunostaining for vimentin was positive in all patients, ALK was negative in all patients, and pancytokeratin positive in only 2 patients. During follow-up, 12 patients (75%) developed tumor recurrence, 9 patients (56%) tumor progression, and 6 patients (37.5%) died of bladder cancer. Median period from the finding of IPT to tumor recurrence was 16 months, to progression 7 months, and to mortality 26 months.
Conclusions |
The finding of IPT in a patient with a history of bladder cancer is associated with a high risk of tumor recurrence, progression, and cancer-related mortality. Second- and possibly third-look bladder biopsies should be considered. The unique characteristics of IPT in patients with a history of bladder cancer suggest that this is a separate disease entity.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 69 - N° 6
P. 1064-1067 - juin 2007 Regresar al número
Artículo precedente
- Tumor Location Does Not Affect Long-Term Renal Function After Partial Nephrectomy
- Joseph A. Pettus, David S. Sharp, Ofer Yossepowitch, Lee R. Schacter, Michael N. Ferrandino, Mark E. Snyder, Ariadne M. Bach, Paul Russo
- Early-Stage Bladder Cancer Surveillance Does Not Improve Survival If High-Risk Patients Are Permitted to Progress to Muscle Invasion
- Cheryl T. Lee, Rodney L. Dunn, Collette Ingold, James E. Montie, David P. Wood
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?